Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Janux Therapeutics, Inc.

Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to better treat patients suffering from cancer. Janux’s initial focus is on developing a novel class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets. While TCE therapeutics have displayed potent anti-tumor activity in hematological cancers, developing TCEs to treat solid tumors have faced challenges due to the limitations of prior TCE technologies, namely (i) overactivation of the immune system leading to cytokine release syndrome, (ii) on-target, healthy tissue toxicities, and (iii) poor pharmacokinetics leading to short half-life. Janux is using its TRACTr platform technology to engineer product candidates designed to overcome these limitations. Janux is developing a broad pipeline with lead programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2), with all of its programs currently in the IND-enabling or discovery stage.

EcoR1 Capital

Surveyor Capital

Avalon Ventures

Hartford HealthCare Endowment

Samsara BioCapital

Biotechnology Value Fund

Bregua Corporation

BVF Partners

OrbiMed

Logos Capital

RA Capital Management

Janux Therapeutics

Today we honor Dr. Martin Luther King Jr. by taking the day to volunteer and celebrate the civil rights leader’s life and legacy. #MLKDay is the only federal holiday designated as a National Day of Service. By volunteering to improve our communities and valuing and respecting all, we honor Dr. King and work together to create a more just and equitable society. 

Visit @AmeriCorps, to find out more about #MLKDayOfService: https://lnkd.in/gX9pXAph

Congrats to Co-Founder Thomas DiRaimondo, Ph.D., on his promotion to Chief Scientific Officer!  

“Tommy was essential in our initial efforts to discover and engineer a tumor-activated technology for solid tumors and has since played a critical role in optimizing the applications for our #TRACTr and #TRACIr platforms while supporting our clinical programs.”

We look forward to his further transformative contributions as we continue to advance our platforms and preclinical pipeline.

Read the release here: https://lnkd.in/dwGhatDa

We are grateful to our team for a great year! Janux will be closed for the holiday so we can spend time with our family and friends. We will return refreshed and ready in the New Year to continue our mission of developing meaningful new immunotherapies to improve outcomes for those fighting cancer.

#LifeatJanux #HappyHolidays

As #Movember2023 comes to a close, we want to thank everyone who joined and supported us in raising awareness for #prostatecancer and #menshealth. For Janux, #Movember helps fuel our inspiration and mission to develop meaningful new immunotherapies to improve outcomes in #mCRPC. 
 
#ProstateCancerAwareness

For International #PrideInSTEM Day, we share our support for #EqualityInSTEM and the LGBTQIA+ community 🏳️🌈. Embracing diversity, in all its forms, is vital for the future of scientific innovation.

Learn more about Pride in STEM - https://prideinstem.org/

Janux is participating in #Movember2023 to raise awareness for #prostatecancer. Here’s photos from our team members that are growing mustaches – some from Day 0 and 15! 

Early detection is key. Understand your risk and when to take action: https://lnkd.in/gPykynKt 

#prostatecancerawareness #GoJanux #Movember

Today we announced our Q3 2023 financial results and business highlights. Enrollment is ongoing for our PSMA-TRACTr (JANX007) and EGFR-TRACTr (JANX008) #clinicaltrials. With a strong financial foundation, we're well-positioned to advance our innovative cancer #immunotherapies.
 
Read the full press release for more details: https://lnkd.in/gmvkquyf
 
$JANX #Q3Earnings #ProstateCancer #TRACTr #TRACIr #TCellEngagers

#Movember2023 has arrived, and Janux is proud to participate in raising awareness for #menshealth and #prostatecancer. Learn more about #Movember and prostate cancer here: https://lnkd.in/gPykynKt  

We will share more progress on our mustaches 👨🦰 later in the month!  

#MensHealthAwareness #ProstateCancerAwareness #GoJanux

At Janux, we believe that each member of the team contributes to our overall mission. We succeed as a team, and we grow as a team. Come join us!

#SucceedAtJanux #GrowAtJanux

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue			3.64M -	8.61M 136.79%	8.08M 6.14%
cost of revenue					1.96M -
gross profit			3.64M -	8.61M 136.79%	6.13M 28.84%
selling and marketing expenses
general and administrative expenses	772K -	1.80M 133.42%	10.33M 473.20%	22.26M 115.53%	26.14M 17.42%
selling general and administrative expenses	772K -	1.80M 133.42%	10.33M 473.20%	22.26M 115.53%	26.14M 17.42%
research and development expenses	3.00M -	3.04M 1.40%	26.24M 762.78%	53.44M 103.69%	54.92M 2.77%
other expenses		-1.74M -	257K 114.81%	4.03M 1,468.87%
cost and expenses	3.77M -	4.84M 28.43%	36.57M 655.03%	75.70M 107.03%	81.06M 7.08%
operating expenses	3.77M -	4.84M 28.43%	36.57M 655.03%	75.70M 107.03%	81.06M 7.08%
interest expense	233K -	206K 11.59%		4.03M -
ebitda	-3.77M -	-6.57M 74.37%	-32.93M 401.58%	-67.09M 103.74%	-71.02M 5.86%
operating income	-3.77M -	-4.84M 28.43%	-32.93M 579.93%	-67.09M 103.74%	-72.98M 8.78%
depreciation and amortization	6K -	-1.72M 28,800%	113K 106.56%	841K 644.25%	1.96M 132.46%
total other income expenses net	-233K -	-1.94M 733.05%	257K 113.24%	4.03M 1,468.87%	14.69M 264.24%
income before tax	-4.00M -	-6.78M 69.43%	-32.67M 381.60%	-63.06M 93.01%	-58.29M 7.56%
income tax expense	233K -	-1.53M 756.22%	-113K 92.61%	-8.90M 7,780.53%
net income	-4.24M -	-5.25M 24.03%	-32.56M 519.58%	-54.15M 66.33%	-58.29M 7.64%
weighted average shs out	6.42M -	12.47M 94.42%	23.53M 88.65%	41.47M 76.24%	44.02M 6.14%
weighted average shs out dil	6.42M -	12.47M 94.42%	23.53M 88.65%	41.47M 76.24%	44.02M 6.14%
eps	-0.66 -	-0.42 36.36%	-1.38 228.57%	-1.31 5.07%	-1.32 0.76%
epsdiluted	-0.66 -	-0.42 36.36%	-1.38 228.57%	-1.31 5.07%	-1.32 0.76%

COM:JANUXRX

Janux Therapeutics

Last Close

46.50

22/11 21:00

Market Cap

2.15B

Beta: -

Volume Today

797.30K

Avg: -

Preview